secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0000950170-24-123703
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari shareholders approve Peak Bio merger; close targeted Nov 13, Nasdaq listing risk seen removed
--------------------------------------------------------------------------------

- All six merger proposals passed with ~99% of vote; 14.6B shares for Merger Allotment.
- Transaction expected to close on November 13, 2024.
- Upon close, Akari expects to remedy Nasdaq shareholder deficiency, removing delisting risk.
- All-stock merger structured for ~50/50 ownership between Akari and Peak Bio holders.
- Combined entity to operate as Akari Therapeutics, trading as AKTX on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024123703/0000950170-24-123703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024123703/aktx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer